Loading stock data…
Spruce Biosciences, Inc. (SPRB)
$43.08-1.91 (-4.25%)
Market ClosedLast close Jul 24
Spruce Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spruce Biosciences, Inc. in the Healthcare sector is trading at $43.08 with a market capitalization of $141M. Wall Street consensus targets $151.00 (8 analysts), implying a +250.5% move over the next 12 months. The stock is currently near its 52-week low of $7.00, remaining 43.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +250.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 25) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.99M↓ | -$11.10M↓ | -$8.23M↓ | -$2.69M↑ | -$14.49M |
| Net Income | -$12.27M↑ | -$14.65M↓ | -$8.21M↓ | -$2.07M↑ | -$14.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$141.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.34%
Volume
Today's trading volume
106,654
Recent News
American Express, Biogen upgraded: Wall Street's top analyst calls
American Express, Biogen upgraded: Wall Street's top analyst calls
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric, Palantir Technologies, Roku, and More
Pre-Market Stock Futures: Futures are trading modestly higher after a stunning opening to the week, as all major indices rocketed higher. The announcement of a cease-fire deal with Iran, which the leaders in that country acknowledged, called for reopening the Strait of Hormuz toll-free. While details will still be worked out over the next ... Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric,
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.